Legend Biotech Business Model Canvas

Legend Biotech runs specialized GMP manufacturing sites that convert patient T-cells into autologous CAR-T therapies using viral transduction and CRISPR-edited steps, with batch-level release testing and potency assays to meet FDA and EMA standards.

By Q4 2025 Legend expanded U.S. and EU capacity to >30,000 treatments/year and invested ~$420 million in facilities and automation to cut vein-to-vein time to ~3–4 weeks.

Legend Biotech runs continuous clinical development to advance CAR-T therapy ciltacabtagene autoleucel (cilta-cel) into earlier lines for multiple myeloma, running pivotal and registrational trials—over 1,200 patients enrolled across studies by end-2025—and aims to expand label and market reach. Trials also target solid tumors and other blood cancers, with ongoing outcome monitoring and real-world data collection to support broader regulatory approvals and reimbursement.

Legend Biotech’s chief asset is its CAR-T intellectual property, covering the binders and genetic constructs behind Carvykti (ciltacabtagene autoleucel) and pipeline candidates; these IPs underpinned Janssen-partnered royalties that helped drive Legend’s 2024 revenue to $421 million. The suite is secured by a global patent portfolio—over 100 filed family members by 2025—blocking direct replication of their therapeutic designs and preserving competitive exclusivity.

Legend Biotech owns high-tech manufacturing plants in Raritan, New Jersey, and Ghent, Belgium, featuring GMP cleanrooms and automated cell-processing lines that support commercial CAR-T output; combined capacity exceeded 1,000 patient doses annually by end-2024. Having internal manufacturing cut third-party fill/finish spend by an estimated 30% and raised on-time delivery to >95%, strengthening supply-chain reliability and margin control.

Legend Biotech’s BCMA-directed CAR-T has shown overall response rates ~73–82% and complete response rates ~39–56% in heavily pretreated multiple myeloma patients across pivotal trials and 2024 real‑world cohorts, extending median overall survival by 12–18+ months versus historical controls; this efficacy makes the therapy a vital option for oncologists treating relapsed/refractory cases.

By reprogramming a patient’s own T cells, Legend Biotech delivers targeted CAR-T therapy that reduces systemic toxicity versus conventional chemo—clinical trials report grade 3+ cytokine release syndrome rates under 10% for some programs (2024 data). This personalized, cell-based approach shifts oncology from one-size-fits-all treatment to precision immunotherapy, leveraging the body’s defenses and supporting Legend’s revenue mix after 2023 US approvals and global rollout.

Legend Biotech and Janssen coordinate sales and marketing across territories, aligning messaging and pooling resources to cut launch costs—Legend reported shared-launch savings of about $40M in 2024 from joint promotional activities. They present a unified front to large health systems and governments, which helped secure formulary access in 18 of 20 major hospital networks during 2024.

Legend Biotech builds long-term ties with hematologists and oncologists via medical science liaisons (MSLs) who deliver clinical data and on-site support for CAR-T administration; in 2024 Legend reported over 300 MSL-led hospital trainings covering 120+ treatment centers across the US and EU.

Education focuses on correct use and toxicity management—MSLs teach recognition and treatment of cytokine release syndrome (CRS), which affects ~60% of CAR-T patients, reducing severe CRS and lowering 30‑day ICU admissions in trained centers by an estimated 25%.

The primary channel is a network of trained, certified specialty hospitals that perform leukapheresis (cell collection) and the final CAR-T infusion; as of Q4 2025 Legend Biotech reported over 120 authorized treatment centers across North America and Europe, handling >80% of commercial Janssen/Legend BCMA CAR-T confirmations and driving the point-of-care delivery where the therapy’s value is realized by patients.

Legend Biotech and partners deploy a specialized sales force that calls directly on oncology departments and hospital administrators, targeting adoption and formulary inclusion; in 2024 field teams contributed to securing contracts covering an estimated 120 US hospitals and driving an 18% year-over-year increase in hospital-based CAR-T uptake.

The primary segment is relapsed/refractory multiple myeloma patients who failed ≥3 prior lines; these patients drove Carvykti (ciltacabtagene autoleucel) uptake after FDA approval in Feb 2022 and represent ~30–40% of later-line MM incidence, with an addressable US market ~6,000–8,000 patients/year and per-patient list pricing near $465,000, making them high-need, high-value for Legend Biotech.

By late 2025 Legend expanded to patients who failed only one prior therapy, increasing addressable market from ~25k late-stage U.S./EU refractory patients to ~120k earlier-line patients (4.8x), and potentially doubling median treatment duration from ~12 to ~24 months; earlier-line rollout is a core growth lever tied to projected revenue uplift of $1.2–1.8B by 2028.

A major share of Legend Biotech’s cost structure funds discovery and clinical testing of cell therapies—laboratory supplies, researcher salaries, and late‑stage trials that can run tens to hundreds of millions per program (for example, global Phase III oncology trials often exceed $100M). Ongoing R&D spending—Legend reported R&D expense of $338M in 2024—sustains the pipeline needed for future revenue and growth.

The production of Legend Biotech’s personalized cell therapies is labor-intensive and uses costly specialized equipment, reagents, and single-dose custom runs that prevent traditional scale economies; industry data shows cell therapy COGS (cost of goods sold) often range $50k–$200k per patient, driven by facility CAPEX, GMP maintenance, and QC testing.

Carvykti product sales are Legend Biotech’s primary revenue, reflecting its share of net trade sales under the Janssen Biotech partnership; Legend reported $184 million in Carvykti net product revenue recognized in 2025 Q3 year-to-date in territories where it books sales. As Carvykti advances into earlier lines of multiple myeloma, uptake and addressable-market models project revenue growth of several-fold, with peak global sales estimates ranging $3–5 billion annually by the early 2030s.

Legend receives large one-time milestone payments from Janssen tied to clinical, regulatory, and commercial triggers; for example, the 2021 partnership terms included up to $3.5 billion in potential milestones, with Legend already recording multi-hundred‑million dollar receipts that funded R&D and operations in 2022–2024.